Look again at that dot. That's here. That's home. That's us. On it everyone you love, everyone you know, everyone you ever heard of, every human being who ever was, lived out their lives.
The aggregate of our joy and suffering, thousands of confident religions, ideologies, and economic doctrines, every hunter and forager, every hero and coward, every creator and destroyer of civilization, every king and peasant, every young couple in love, every mother and father,
...hopeful child, inventor and explorer, every teacher of morals, every corrupt politician, every "superstar," every "supreme leader," every saint and sinner in the history of our species lived there--on a mote of dust suspended in a sunbeam.
The Earth is a very small stage in a vast cosmic arena. Think of the rivers of blood spilled by all those generals and emperors so that, in glory and triumph, they could become the momentary masters of a fraction of a dot.
Think of the endless cruelties visited by the inhabitants of one corner of this pixel on the scarcely distinguishable inhabitants of some other corner, how frequent their misunderstandings, how eager they are to kill one another, how fervent their hatreds.
Our posturings, our imagined self-importance, the delusion that we have some privileged position in the Universe, are challenged by this point of pale light. Our planet is a lonely speck in the great enveloping cosmic dark.
In our obscurity, in all this vastness, there is no hint that help will come from elsewhere to save us from ourselves. The Earth is the only world known so far to harbor life. There is nowhere else, at least in the near future, to which our species could migrate.
Visit, yes. Settle, not yet. Like it or not, for the moment the Earth is where we make our stand.
It has been said that astronomy is a humbling and character-building experience.
There is perhaps no better demonstration of the folly of human conceits than this distant image of our tiny world. To me, it underscores our responsibility to deal more kindly with one another, and to preserve and cherish the pale blue dot, the only home we've ever known.
— Carl Sagan, Pale Blue Dot, 1994
Picture taken by Voyager 1
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Q1FY22 concall was today for 🌋🌋. My key takeaways 👇👇
1⃣ Revenue & margin 🔻
In b/w lines:
Multiple factors for affecting both. Unit 3 has been commercialised, but not ramped up. Operating de-leverage at play. CMS revenue lumpy. As biz mix changes, so do margins.
Some CMS revenue postponed due to complex nature of projects (more on that later).
2⃣ Medium term guidance of 15-20% topline growth and 20% EBITDA margins
In b/w lines:
What we need to understand is that this is a very lumpy biz, even YoY there wont always be 15% growth.
Prices for Generic APIs are as per market movements. CMS revenues are lumpy. How can a management predict when will the Patent protected innovator molecule get commercialised? They simply cannot. With unit 3 ramping up & CMS revenue coming up, i fully expect 20% EBITDA margins
#IDFCFIRSTBank FIRST concall was right now. My key takeaways:
1. Credit costs of 2.5% in FY22, 2% in steady state.
In b/w lines: Bank has incremental NIMs of >9% which will support 2% credit costs. 1800cr provisions taken in Q1 represent a very conservative approach
A 850cr mumbai toll road account slipped into NPA due to covid lockdowns. There were partial payments. Expect it to come out of NPA post covid wave. VI exposure credit costs not included in 2.5% guidance.
2. Runway for growth is long
In b/w lines: Can grow loan book at 25% for a long time. Expecting 18-20% ROE from retail lending alone in steady state. CASA will also continue to grow enough to support retail lending needs. Enough cash right now.
#lauruslabs Q1 results key takeaways: 1. Diversification away from ARV
In b/w lines:
Currently 85% of filings in US/EU are ARV. This represents 11B$ of market opportunity.
But products under development (which represent 37B$ of opportunity) are skewed 80/20 for non-arv.
2. CDMO segment growth can surprise on upside.
In b/w lines:
the 195cr revenue in Q1 did not contain any one-offs. This represents a very good growth YoY growth of ~100%. Generally Q4 is strongest and Q1 this time was even higher. Only 4 products commercialised.
Huge potential for the 40+ products in pipeline. expecting this to drive growth in US and EU markets.
First let us understand the types of products the company makes. This is a chemicals company. The primary line of products they are into is called PTC: Phase transfer agents. Before I explain what that is, let us do a small dive into chemistry.
The basic building blocks of matter (everything around you) are atoms. They come in 118 flavors, called elements. The water you drive is made of 2 Hydrogen atoms & 1 Oxygen atom: H2O.
Although question was addressed to Tariq, who answered it beautifully just wanted to add my thoughts:
Future belongs to those who specialise. Whether we look at doctors or engineers, everyone wants a specialist not a generalist.
Why should companies be any different?
Everyone in value chain has a specific function.
Cdmo does not do the research, so many innovators keep the research (discovery of candidate good enough for phase 1 trial) in house & outsouce the cumbersome development and manufacturing
Some others even outsource the research & become collaborators and move up the value chain. This is where syngene and similar CRO come into the picture.
As a junior engineer you start out writing thousands of lines of code every quarter.